Brief: DURECT Completes Enrollment In Phase 2b AHFIRM Trial Of Larsucosterol In Alcohol-Associated Hepatitis
07/06/2023 11:21
June 7 (Reuters) - DURECT Corp DRRX.O :
* DURECT COMPLETES ENROLLMENT IN PHASE 2B AHFIRM TRIAL OF
LARSUCOSTEROL IN ALCOHOL-ASSOCIATED HEPATITIS
* DURECT CORP - TOPLINE DATA ANTICIPATED IN Q4 2023
Source text for Eikon: ID:nPn7rn0sda
Further company coverage: DRRX.O
Recent news on DURECT
See all newsBrief: Bausch Health Completes Acquisition Of Durect Corporation, Expanding Late-Stage Liver Disease Portfolio
Durect Corp Reports Results For The Quarter Ended June 30: Earnings Summary
Brief: Durect Bausch Health Extend Tender Offer Date To Aug 12 - SEC Filing
Durect Corp Expected To Post A Loss Of 12 Cents A Share: Earnings Preview
Durect Corp Reports Results For The Quarter Ended March 31: Earnings Summary